Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia.

The Cochrane Database of Systematic Reviews
Myrto T SamaraStefan Leucht

Abstract

Many people with schizophrenia do not respond to an initially prescribed antipsychotic drug. In such cases, one treatment strategy could be to increase the antipsychotic dose; and another strategy could be to switch to a different antipsychotic drug. To examine the efficacy of increasing the antipsychotic dose versus switching the antipsychotic drug in the treatment of non-responsive people with schizophrenia. We searched the Cochrane Schizophrenia Group Trials Register (10 June 2014, 6 October 2015, and 30 March 2017). We examined references of all included studies for further trials. All relevant randomised controlled trials (RCTs) comparing increasing the antipsychotic dose versus switching to a different antipsychotic drug for people with schizophrenia who have not responded to their initial antipsychotic treatment. At least two review authors independently extracted data. We analysed dichotomous data using relative risks (RR) and their 95% confidence intervals (CIs). We analysed continuous data using mean differences (MD) and their 95% CIs. We assessed risk of bias for included studies and used GRADE to create a 'Summary of findings' table. We include one RCT with relevant data on 29 participants in this review. The trial ...Continue Reading

References

Nov 1, 1992·Journal of General Internal Medicine·G W DivineL M Frazier
Jan 1, 1988·Archives of General Psychiatry·R J BaldessariniM H Teicher
Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Jul 1, 1982·Archives of General Psychiatry·N C Andreasen, S Olsen
Nov 9, 1996·BMJ : British Medical Journal·D G Altman, J M Bland
Sep 26, 1997·BMJ : British Medical Journal·J M Bland, S M Kerry
Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Jan 16, 1998·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J Arnt, T Skarsfeldt
Jun 18, 1999·The Journal of Clinical Psychiatry·D Naber
Dec 1, 1999·Biological Psychiatry·J M Kane
Feb 7, 2001·The British Journal of Psychiatry : the Journal of Mental Science·M MarshallM Fenton
Apr 20, 2001·JAMA : the Journal of the American Medical Association·D MoherUNKNOWN CONSORT Group (Consolidated Standards of Reporting Trials)
Mar 27, 2002·International Journal of Epidemiology·Diana R ElbourneAndy Vail
Sep 27, 2002·Statistics in Medicine·Allan Donner, Neil Klar
May 21, 2003·The Journal of Clinical Psychiatry·Peter J WeidenRichard L O'Sullivan
Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman
Nov 19, 2003·Journal of Clinical Psychopharmacology·Robert R ConleyWilliam T Carpenter
Dec 10, 2003·Archives of General Psychiatry·Ofer AgidRobert B Zipursky
Jun 30, 2004·CNS Drugs·Bruce J KinonPeter F Buckley
Mar 9, 2005·Archives of General Psychiatry·Brian A PalmerJohn Michael Bostwick
Jun 29, 2005·Schizophrenia Research·Stefan LeuchtRolf R Engel
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Sep 22, 2005·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Peter FalkaiUNKNOWN WFSBP Task Force on Treatment Guidelines for Schizophrenia
Oct 4, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Stefan LeuchtRolf Engel
Dec 20, 2005·Journal of Clinical Epidemiology·Toshi A FurukawaNorio Watanabe
Aug 15, 2006·Schizophrenia Bulletin·Stefan LeuchtJohn M Davis
Oct 13, 2006·European Archives of Psychiatry and Clinical Neuroscience·Markus JägerHans-Jürgen Möller
Mar 10, 2009·Schizophrenia Research·Emilio SacchettiUNKNOWN INITIATE Study Group
Nov 6, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Bruce J KinonJohn M Kane
Dec 4, 2009·Schizophrenia Bulletin·Robert W BuchananUNKNOWN Schizophrenia Patient Outcomes Research Team (PORT)
Mar 3, 2010·The American Journal of Psychiatry·Jian-Ping ZhangAnil K Malhotra
Apr 3, 2010·The American Journal of Psychiatry·David M GardnerRoss J Baldessarini
Oct 12, 2010·Psychological Medicine·M CaseB J Kinon
Nov 1, 2011·International Journal of Surgery·David MoherUNKNOWN CONSORT
Jul 28, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanUNKNOWN World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

The Cochrane Database of Systematic Reviews
Myrto T SamaraStefan Leucht
The Cochrane Database of Systematic Reviews
Michael Lacey, Mahesh B Jayaram
The Cochrane Database of Systematic Reviews
Adib EssaliClive E Adams
The Cochrane Database of Systematic Reviews
Julie Broderick, Davy Vancampfort
© 2022 Meta ULC. All rights reserved